Comparative Pharmacology
Head-to-head clinical analysis: EVOXAC versus VUITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOXAC versus VUITY.
EVOXAC vs VUITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist. It induces miosis by contracting the iris sphincter muscle, increasing the eye's depth of focus and improving near visual acuity. It acts via the ciliary muscle to reduce the diameter of the pupil, creating a pinhole effect that enhances depth of focus.
30 mg orally three times daily.
One drop of VUITY (pilocarpine 1.25% ophthalmic solution) instilled into each eye three times daily at approximately 6-8 hour intervals.
None Documented
None Documented
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Terminal half-life: 134 hours (range 110-170 hours). Clinical context: allows once-weekly dosing; steady-state achieved after 2-3 months.
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
Primarily via hepatic metabolism; inactive metabolites excreted in urine (approximately 90%) and feces (approximately 10%).
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist